PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.68 - 0.75
0.33 - 0.86
18.36M / 4.66M (Avg.)
34.50 | 0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
69.45%
Revenue growth above 1.5x 0376.HK's 20.52%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
283.79%
Gross profit growth above 1.5x 0376.HK's 20.52%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
229.63%
EBIT growth above 1.5x 0376.HK's 117.51%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
229.63%
Operating income growth above 1.5x 0376.HK's 117.51%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
183.19%
Net income growth at 50-75% of 0376.HK's 366.32%. Martin Whitman would question fundamental disadvantages in expenses or demand.
171.60%
EPS growth at 50-75% of 0376.HK's 341.18%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
171.60%
Diluted EPS growth at 50-75% of 0376.HK's 341.18%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
16.23%
Share count expansion well above 0376.HK's 4.24%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
16.16%
Diluted share count expanding well above 0376.HK's 4.24%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-5.02%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-3.95%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-25.20%
Negative 10Y revenue/share CAGR while 0376.HK stands at 445.66%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-14.92%
Negative 5Y CAGR while 0376.HK stands at 2922.05%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
78.46%
3Y revenue/share CAGR under 50% of 0376.HK's 3654.96%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-879.87%
Negative 10Y OCF/share CAGR while 0376.HK stands at 294.63%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-38.06%
Negative 5Y OCF/share CAGR while 0376.HK is at 1146.73%. Joel Greenblatt would question the firm’s operational model or cost structure.
-2020.15%
Negative 3Y OCF/share CAGR while 0376.HK stands at 434.06%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
618.94%
Net income/share CAGR above 1.5x 0376.HK's 239.47% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
82.63%
Below 50% of 0376.HK's 251.16%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
135.49%
Below 50% of 0376.HK's 345.61%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
109.13%
10Y equity/share CAGR at 50-75% of 0376.HK's 215.34%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
-16.14%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
41.33%
Below 50% of 0376.HK's 122.21%. Michael Burry suspects a serious short-term disadvantage in building book value.
-91.69%
Cut dividends over 10 years while 0376.HK stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.95%
AR growth of 8.95% while 0376.HK is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
-33.37%
Inventory is declining while 0376.HK stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-10.25%
Negative asset growth while 0376.HK invests at 11.44%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-1.50%
We have a declining book value while 0376.HK shows 17.73%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-55.61%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-0.41%
Our R&D shrinks while 0376.HK invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
71.83%
SG&A growth well above 0376.HK's 17.90%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.